Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02653469
Other study ID # SMC 2015-06-015
Secondary ID
Status Completed
Phase N/A
First received October 20, 2015
Last updated March 2, 2016
Start date September 2015
Est. completion date February 2016

Study information

Verified date March 2016
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

Pulse pressure variation (PPV) is a well-known and widely used dynamic preload indicator based on heart-lung interaction to predict fluid responsiveness. Generally, patients are considered to be fluid-responsive when the PPV value larger than 11-13%. However, several previous researches demonstrated that there is a zone of uncertainty (grey zone) in PPV. To predict fluid-responsiveness accurately in the patients with PPV within grey zone (9-13%), the investigators would evaluate the augmented PPV using augmented ventilation.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Adult patients undergoing elective open laparotomy surgery.

Exclusion Criteria:

- Irregular heart beats,

- cardiac arrhythmia,

- moderate or severe valvular heart disease,

- preoperative left ventriular ejection fraction less than 40%,

- moderate t severe obstructive pulmonary disease,

- preoperative need of inotropics infusion,

- preoperative serum Cr > 1.3ml/dl,

- moderate to severe renal or liver disease,

- acute lung injury or acute lung problem,

- coexisting open chest condition,

- severe bradycardia,

- patients with spontaneous breathing

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
Augmented ventilation
When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
Fluid loading
We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Augmented PPV (Pulse Pressure Variation) to predict fluid responsiveness Augmented ventilation (12ml/kg) will be performed when the participant's PPV is within grey zone (9-13%). PPV value will be collected automatically by Intelivue philips patient monitor. Percentage changes in stroke volume index by EV1000 according to fluid loading were used as principal indicators of fluid responsiveness. Patients were classified as responders or non-responders when increases in SVI were = 10% or <10% after volume loading (crystalloid iv 6ml/kg). To test the abilities of augmented PPV to predict fluid responsiveness, areas under the receiver operating characteristics (ROC) curves of the responders [area under the curve (AUC) = 0.5: no better than chance, no prediction possible; AUC = 1.0: best possible prediction] will be calculated. within 2 min from augmented ventilation No
Secondary Conventional baseline PPV to predict fluid responsiveness PPV value will be collected automatically by Intelivue philips patient monitor. when patients PPV in grey zone, before augmented ventilation No
See also
  Status Clinical Trial Phase
Recruiting NCT05185947 - Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer Phase 2
Completed NCT02309944 - Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients N/A
Withdrawn NCT00328757 - Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer Phase 3
Completed NCT02728830 - A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Early Phase 1
Completed NCT02935530 - Thromboprophylaxis After Surgery for Gynecologic Malignancy in China Phase 3
Completed NCT02918461 - Emerging From the Haze for Gynecologic Cancer Survivors N/A
Completed NCT02786524 - Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy N/A
Terminated NCT04493619 - PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT03101280 - A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer Phase 1